Aardvark says FDA lifted clinical hold on ARD-101 for Prader-Willi hyperphagia
Aardvark plans an FDA meeting in early 2027 on its ARD-101 development plan and expects to resume PWS clinical work that year, with $60.3 million in cash as of September 30, 2026.
SEC filing